Thread by @TumorBoardTues

1/ 🌟 Calling #Oncology HCPs 🌟

🆕 #TumorBoardTuesday #Tweetorial
🚨 🧬 HER2 in Breast Cancer
👥 @MPishvaian & @ErikaHamilton9

Supported by educational grants from AstraZeneca Pharmaceuticals & Daiichi Sankyo, Inc.

CME ℹ️ bit.ly/3ecVOcC

🗣️ What's your specialty ⁉️

2/ 🗒️ Full reference list & glossary 👉 bit.ly/3yMvIGW

🔑 Key #CME & faculty info 👇, full info 👉 bit.ly/3ecVOcC

#TumorBoardTuesday

3/ 🛑 POLL 🛑

🤔 In a Ph3 trial, which agent has demonstrated an ORR of nearly 80% ❓
#TumorBoardTuesday

4/ T-DXd = correct! #TumorBoardTuesday

⭐️ Preferred 2L Tx 💊 for 🧬 HER2➕ 🔁 unresectable BC/mBC

📌 DESTINY-Breast03, open-label, Ph3 trial
👉 2L T-DXd 🆚 T-DM1 in prev-Tx, HER2➕ mBC

⬆️ PFS
✖️ OS not significant, trend encouraging
🗒️ Early data; TEAE rate similar
⬆️ ILD

5/ T-DM1 now 2L ‘other recommended regimen’ 👍
for patients w/ 🧬 HER2➕ 🔁 unresectable or mBC

🩺 Survival benefits meaningful but modest
✅ Improvement 🆚 lapatinib/capecitabine
👉 mPFS: 3.2mo
👉 mOS: 5.8mo

🚫 No SOC for progression after Tx 💊 w/ T-DM1
#TumorBoardTuesday

6/ 🛑 POLL 🛑

🤔 In a Ph2 trial, which agent has demonstrated a PFS at 1 year of nearly 25% in 🧑 patients w/ 🧠 brain mets ❓
#TumorBoardTuesday

7/ Tucatinib = correct! #TumorBoardTuesday

✅ FDA-approved 2L Tx 💊
🧑 Patients w/ 🧬 HER2➕ advanced unresectable or mBC

📌 HER2CLIMB: Ph2 trial 🆚 placebo in prev-Tx patients
⬆️ PFS & OS ± 🧠 mets
📑 NCCN 3L ‘other recommended'; 2L ‘preferred’ for patients w/ 🧠 mets

8/ ‼️ Recently ✅ approved agents for 3L Tx 💊 for 🧑 Patients w/ 🧬 HER2➕ 🔁 unresectable or mBC

👉 T-DXd
👉 Margetuximab

#TumorBoardTuesday

9/ 🛑 POLL 🛑

🤔 Among AEs of special interest, which was the most common w/ T-DXd Tx 💊 ❓
#TumorBoardTuesday

10/ ILD = correct! #TumorBoardTuesday

📌 DESTINY-Breast01
🧪 Single-arm, Ph2 trial of T-DXd
🧑 Patients w/ 🧬 HER2➕ mBC previously Tx 💊 w/ T-DM1

⭐️ Durable antitumor activity ‼️
🫁 Incidence of ILD warrants attention to & monitoring of pulmonary symptoms

11/ 👉 Next: DESTINY-Breast02

🗒️ Open-label, randomized, Ph3 trial
🔎 T-DXd 🆚 standard Tx 💊
🧑 Patients w/ 🧬 HER2➕ unresectable &/or mBC previously Tx 💊 w/ T-DM1

✅ Trial to confirm results of Ph2 DESTINY-Breast01 & support FDA approval
#TumoBoardTuesday

12/ #TumorBoardTuesday 📌 SOPHIA

🔎 Ph3 trial of margetuximab ➕ chemo 🆚 trastuzumab ➕ chemo
🧑 Patients w/ aBC
💊 Previously Tx w/ 2 or more anti-HER2 Tx & 1-3 prior Tx for mBC

✅ PFS statistically significantly improved
✖️ OS not significant
👍 Acceptable safety profile

13/ ‼️ Experimental Tx 🧪 💊 #TumorBoardTuesday

📌 Recently approved agents undergoing further evaluation 📊

👉 T-DXd
👉 Tucatinib (recruiting)
👉 Novel agent 🌟 T-duocarmazine 🌟

14/ ‼️ HER2CLIMB-02

📊 Randomized, double-blind, Ph3 trial
💊 T-DM1 ➕/➖ tucatinib
🧑 Patients w/ unresectable locally ⬆️ a/mBC

🥅 Goal: determine utility of tucatinib in earlier lines of Tx 💊

📌 Status: recruiting
#TumorBoardTuesday

15/ ‼️ HER2CLIMB-04

🔎 Single-arm, Ph2 trial
🧐 Tucatinib ➕ T-DXd
🧑 Patients w/ unresectable, locally-advanced or metastatic 🧬 HER2➕ BC

🥅 Goal: determine efficacy & 🦺 safety of tucatinib ➕ T-DXd

📌 Status: recruiting
#TumorBoardTuesday

16/ 🧭 CompassHER2 RD

🧐 Randomized, double-blind, Ph3 trial
🔎 T-DM1 ➕/➖ tucatinib
🧑 Patients w/ ⬆️ high-risk, 🧬 HER2➕ BC

🥅 Goal: determine superiority of tucatinib ➕ T-DM1 to T-DM1 alone

📌 Status: recruiting
#TumorBoardTuesday

17/ 🌷 TULIP

🗒️ Open-label, randomized, Ph3 trial
🧪 T-duocarmazine 🆚 physician’s choice i
🧑 Patients w/ 🧬HER2➕ unresectable locally a/mBC

🥅 Purpose: demonstrate superiority of T-duocarmazine to physician’s choice in prolonging PFS
#TumorBoardTuesday

18/ 🔑🔑🔑 Key points ‼️ #TumorBoardTuesday

📌 T-DXd emerged as current SOC in 2L

📌 Multiple other approved Tx 💊
👉Tucatinib combo
👉T-DM1

📌 Clinical trials are ongoing to evaluate 🔍
⭐️ T-DXd & tucatinib in earlier lines
⭐️ T-DXd as adjuvant therapy
⭐️ Novel ADCs

19/ Thank you 🙏 for joining this 🧬 HER2 in BC #TumorBoardTuesday #Tweetorial! 
 
👉 Knowledge on the go - 🆓 resources: integrityce.com/HER2resources

‼️ Pick up your #CME 👉 by answering 3 quick questions🧠❓

💥 Voila 💥

20/ #Posttest Q 1⃣ #CME #TumorBoardTuesday

🤔 In a Ph3 trial, which agent has demonstrated an ORR of nearly 80% ❓

Claim credit: bit.ly/3mrBl8z

21/ #Posttest Q 2⃣ #CME #TumorBoardTuesday

🤔 In a Ph2 trial, which agent has demonstrated a PFS at 1 year of nearly 25% in 🧑 patients w/ 🧠 brain mets ❓

Claim credit: bit.ly/3mrBl8z

22/ #Posttest Q 3⃣ #CME #TumorBoardTuesday

🤔 Among AEs of special interest, which was the most common w/ T-DXd Tx ❓

Claim credit: bit.ly/3mrBl8z

23/ 🙏 for joining this #TumorBoardTuesday #Tweetorial ‼️
 
👉 Knowledge on the go - 🆓 resources: integrityce.com/HER2resources

💥 Stay tuned for more from @TumorBoardTues

➡️ Now weigh in on tonight's #PancChat ‼️ ⬅️

@letswinpc @PanCAN @MPishvaian

10b/ Take a 👀 at the DESTINY-Breast01 Trial Data 📊 #TumorBoardTuesday